EPISODE · Jun 10, 2026 · 1H 20M
Dead Cells, Fake Labels, and The Stem Cell Industry's Dirty Secret | Ep61 with Jeff Turk
from 90% Healthy · host Klaudia Balogh and Don Moxley
Jeffrey Turk has been inside the stem cell industry long enough to know where the bodies are buried — figuratively speaking.As a disabled veteran, NBC Operations Specialist, and founder of Mount Hydra, Jeff came into this space because stem cells were the only thing that helped him. What he found was an industry riddled with counterfeit products, dead cells dressed up in premium packaging, and a regulatory gap wide enough to drive a clinic through.This episode is a buyer's guide disguised as a conversation. Jeff breaks down the three tests every biologic product should be able to show you before it goes anywhere near your body, explains why "1 trillion exosomes" is almost always a warning sign, and reveals the graft-versus-host disease risk buried inside cord blood treatments that practitioners are largely not disclosing.He also shares what he believes the next five years look like: customized exosome therapy by biomarker, longevity escape velocity, and off-the-shelf treatments for the cancers that currently carry the worst prognoses.If you or someone you know is considering stem cell or exosome therapy — or you're already a patient wondering if you got what you paid for — this is the episode to send them.The checklist Jeff recommends every patient ask for:Endotoxin test resultsMycoplasma test resultsTwo-week sterility test resultsPost-thaw viability (gold standard: 80%+)Lot number and population doublings (cell age)Cryopreservative confirmation for any Wharton's jelly productCD63/CD81 marker confirmation for exosomesJeff is currently working with AASCM to build a neutral, independent watchdog association for the stem cell industry — and he's offering to help patients and doctors who have questions.Connect with Jeffrey Turk:🌐 mounthydra.comConnect with the hosts of the 90% Healthy:🌐 Klaudia - longevityjournalist.com🌐 Don- trainrecoverwin.com
What this episode covers
Jeffrey Turk has been inside the stem cell industry long enough to know where the bodies are buried — figuratively speaking.As a disabled veteran, NBC Operations Specialist, and founder of Mount Hydra, Jeff came into this space because stem cells were the only thing that helped him. What he found was an industry riddled with counterfeit products, dead cells dressed up in premium packaging, and a regulatory gap wide enough to drive a clinic through.This episode is a buyer's guide disguised as a conversation. Jeff breaks down the three tests every biologic product should be able to show you before it goes anywhere near your body, explains why "1 trillion exosomes" is almost always a warning sign, and reveals the graft-versus-host disease risk buried inside cord blood treatments that practitioners are largely not disclosing.He also shares what he believes the next five years look like: customized exosome therapy by biomarker, longevity escape velocity, and off-the-shelf treatments for the cancers that currently carry the worst prognoses.If you or someone you know is considering stem cell or exosome therapy — or you're already a patient wondering if you got what you paid for — this is the episode to send them.The checklist Jeff recommends every patient ask for:Endotoxin test resultsMycoplasma test resultsTwo-week sterility test resultsPost-thaw viability (gold standard: 80%+)Lot number and population doublings (cell age)Cryopreservative confirmation for any Wharton's jelly productCD63/CD81 marker confirmation for exosomesJeff is currently working with AASCM to build a neutral, independent watchdog association for the stem cell industry — and he's offering to help patients and doctors who have questions.Connect with Jeffrey Turk:🌐 mounthydra.comConnect with the hosts of the 90% Healthy:🌐 Klaudia - longevityjournalist.com🌐 Don- trainrecoverwin.com
NOW PLAYING
Dead Cells, Fake Labels, and The Stem Cell Industry's Dirty Secret | Ep61 with Jeff Turk
No transcript for this episode yet
Similar Episodes
May 25, 2026 ·18m
May 24, 2026 ·23m